Simmons Bank Has $226,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Simmons Bank decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 36.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,093 shares of the medical equipment provider’s stock after selling 1,218 shares during the quarter. Simmons Bank’s holdings in Zimmer Biomet were worth $226,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet during the 3rd quarter worth $28,000. Crewe Advisors LLC acquired a new position in shares of Zimmer Biomet in the first quarter valued at approximately $31,000. Bangor Savings Bank bought a new position in Zimmer Biomet in the 3rd quarter valued at approximately $31,000. Family Firm Inc. acquired a new stake in Zimmer Biomet during the 2nd quarter worth approximately $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Zimmer Biomet during the second quarter valued at $43,000. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ZBH. UBS Group decreased their price target on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a report on Thursday, August 8th. TD Cowen cut their price target on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a report on Friday, September 6th. Wells Fargo & Company lifted their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. BTIG Research cut their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Finally, Royal Bank of Canada lifted their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Stock Down 1.0 %

ZBH stock opened at $108.85 on Friday. The business’s 50 day moving average price is $106.04 and its two-hundred day moving average price is $110.19. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The company has a market capitalization of $21.67 billion, a price-to-earnings ratio of 20.69, a price-to-earnings-growth ratio of 2.02 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $101.47 and a fifty-two week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter last year, the firm earned $1.65 earnings per share. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.